M.A. Crocq

1.4k total citations
34 papers, 736 citations indexed

About

M.A. Crocq is a scholar working on Psychiatry and Mental health, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, M.A. Crocq has authored 34 papers receiving a total of 736 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Psychiatry and Mental health, 6 papers in Molecular Biology and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in M.A. Crocq's work include Schizophrenia research and treatment (10 papers), Bipolar Disorder and Treatment (7 papers) and Neurotransmitter Receptor Influence on Behavior (4 papers). M.A. Crocq is often cited by papers focused on Schizophrenia research and treatment (10 papers), Bipolar Disorder and Treatment (7 papers) and Neurotransmitter Receptor Influence on Behavior (4 papers). M.A. Crocq collaborates with scholars based in France, Germany and United States. M.A. Crocq's co-authors include Déborah Morris-Rosendahl, J.P. Macher, Fabrice Duval, Paul Bailey, Michael Gill, Vishwajit L. Nimgaonkar, Oliver H. Wittekindt, Katalin Kálmán, Pak C. Sham and K. George Chandy and has published in prestigious journals such as Biological Psychiatry, Molecular Psychiatry and Psychopharmacology.

In The Last Decade

M.A. Crocq

31 papers receiving 697 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.A. Crocq France 15 308 302 257 149 86 34 736
Christo Minov Germany 12 302 1.0× 190 0.6× 254 1.0× 77 0.5× 68 0.8× 19 768
Koichi Ohara Japan 17 322 1.0× 315 1.0× 230 0.9× 156 1.0× 207 2.4× 36 888
Hiroshi Suwaki Japan 19 400 1.3× 190 0.6× 326 1.3× 57 0.4× 51 0.6× 85 1.1k
Joachim Scharfetter Austria 12 146 0.5× 280 0.9× 103 0.4× 128 0.9× 63 0.7× 21 499
Timothy L. Holman United States 15 147 0.5× 496 1.6× 152 0.6× 85 0.6× 59 0.7× 22 896
Anna Schuhmacher Germany 18 215 0.7× 161 0.5× 171 0.7× 135 0.9× 81 0.9× 26 731
Rudi Hwang Canada 20 355 1.2× 525 1.7× 250 1.0× 214 1.4× 144 1.7× 33 1.0k
Helge Neidt Germany 15 564 1.8× 217 0.7× 265 1.0× 160 1.1× 174 2.0× 22 984
Osnat Karni Israel 13 145 0.5× 158 0.5× 293 1.1× 211 1.4× 103 1.2× 17 706
M. Lanczik Germany 14 165 0.5× 257 0.9× 107 0.4× 111 0.7× 94 1.1× 28 547

Countries citing papers authored by M.A. Crocq

Since Specialization
Citations

This map shows the geographic impact of M.A. Crocq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.A. Crocq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.A. Crocq more than expected).

Fields of papers citing papers by M.A. Crocq

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.A. Crocq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.A. Crocq. The network helps show where M.A. Crocq may publish in the future.

Co-authorship network of co-authors of M.A. Crocq

This figure shows the co-authorship network connecting the top 25 collaborators of M.A. Crocq. A scholar is included among the top collaborators of M.A. Crocq based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.A. Crocq. M.A. Crocq is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Crocq, M.A.. (2015). Histoire des traitements antipsychotiques à action prolongée dans la schizophrénie. L Encéphale. 41(1). 84–92. 17 indexed citations
2.
Thomas, Simon H. L., Milou D. Drici, Gillian C. Hall, et al.. (2010). Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatrica Scandinavica. 122(5). 345–355. 45 indexed citations
3.
Crocq, M.A., Д. Набер, M Lader, et al.. (2010). Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. European Neuropsychopharmacology. 20(12). 829–838. 19 indexed citations
4.
Limosin, Frédéric, Jean‐Michel Azorin, Marie‐Odile Krebs, et al.. (2008). Données actuelles et modalités d’utilisation de l’aripiprazole dans le traitement de la schizophrénie. L Encéphale. 34(1). 82–92. 2 indexed citations
5.
Crocq, M.A., Vincent Camus, Bruno Millet, et al.. (2008). Potentialités cliniques et perspectives d’utilisation de l’aripiprazole hors de ses champs classiques d’indication. L Encéphale. 34(2). 187–193. 7 indexed citations
6.
Wittekindt, Oliver H., E. Omer Burgert, Michael Knapp, et al.. (1999). Association between hSKCa3 and schizophrenia not confirmed by transmission disequilibrium test in 193 offspring/parents trios. Molecular Psychiatry. 4(3). 267–270. 17 indexed citations
7.
Duval, Fabrice, et al.. (1999). Thyroid axis activity and serotonin function in major depressive episode. European Neuropsychopharmacology. 9. 236–237. 1 indexed citations
8.
Burgert, E. Omer, et al.. (1998). No association between the tyrosine hydroxylase microsatellite marker HUMTH01 and schizophrenia or bipolar I disorder. Psychiatric Genetics. 8(2). 45–48. 19 indexed citations
9.
Chandy, K. George, Emmanuelle Fantino, Oliver H. Wittekindt, et al.. (1998). Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and bipolar disorder?. Molecular Psychiatry. 3(1). 32–37. 178 indexed citations
10.
Delbrück, Sebastian, Sophia Brismar Wendel, Ingrid Grunewald, et al.. (1997). A novel allelic variant of the human serotonin transporter gene regulatory polymorphism. Cytogenetic and Genome Research. 79(3-4). 214–220. 62 indexed citations
11.
Duval, Fabrice, et al.. (1997). Dopamine function and HPA axis activity in psychotic depression. Biological Psychiatry. 42(1). 111S–112S. 1 indexed citations
12.
Griffon, Nathalie, M.A. Crocq, Caroline Pilon, et al.. (1996). Dopamine D3 receptor gene: Organization, transcript variants, and polymorphism associated with schizophrenia. American Journal of Medical Genetics. 67(1). 63–70. 59 indexed citations
13.
Duval, Fabrice, et al.. (1995). Multihormonal responses to apomorphine in mental illness. Psychoneuroendocrinology. 20(4). 365–375. 38 indexed citations
14.
Dawson, E.P., John Powell, Pak C. Sham, et al.. (1995). An association study of a neurotrophic3 (NT‐3) gene polymorphism with schizophrenia. Acta Psychiatrica Scandinavica. 92(6). 425–428. 29 indexed citations
15.
Shaikh, Saleem, David Collier, Pak C. Sham, et al.. (1995). Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. American Journal of Medical Genetics. 60(6). 541–545. 58 indexed citations
16.
Dawson, Elisabeth, John Powell, Markus M. Nöthen, et al.. (1994). An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia. Psychiatric Genetics. 4(4). 215–218. 19 indexed citations
17.
Duval, Fabrice, et al.. (1994). Endocrine responses to D,L- and D-fenfluramine in psychiatry. Biological Psychiatry. 35(9). 646–646. 4 indexed citations
18.
Duval, Fabrice, et al.. (1994). Neuroendocrine profiles of antipsychotic drugs in schizophrenic patients. Biological Psychiatry. 35(9). 649–649. 1 indexed citations
19.
Duval, Fabrice, et al.. (1993). Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients. Psychopharmacology. 110(1-2). 177–180. 12 indexed citations
20.
Duval, Fabrice, et al.. (1992). CIRCADIAN EFFECTS ON THE TSH RESPONSE TO TRH IN DEPRESSED PATIENTS. Clinical Neuropharmacology. 15. 384A–385A. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christo Minov Breakdown of academic impact, for papers by Koichi Ohara Breakdown of academic impact, for papers by Hiroshi Suwaki Breakdown of academic impact, for papers by Joachim Scharfetter Breakdown of academic impact, for papers by Timothy L. Holman Breakdown of academic impact, for papers by Anna Schuhmacher Breakdown of academic impact, for papers by Rudi Hwang Breakdown of academic impact, for papers by Helge Neidt Breakdown of academic impact, for papers by Osnat Karni Breakdown of academic impact, for papers by M. Lanczik
Rankless by CCL
2026